Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patricia P. Lillquist is active.

Publication


Featured researches published by Patricia P. Lillquist.


Cancer Causes & Control | 2002

Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States)

Ikuko Kato; Karen L. Koenig; Roy E. Shore; Mark S. Baptiste; Patricia P. Lillquist; Glauco Frizzera; Jerome S. Burke; Hiroko Watanabe

Objective: To examine whether exposures to anti-inflammatory and non-narcotic analgesic drugs are associated with risk of non-Hodgkins lymphoma (NHL). Methods: A case–control study was conducted among women living in upstate New York. The study involved 376 cases of NHL identified through the New York State Cancer Registry and 463 controls randomly selected from the Medicare beneficiary files and New York State drivers license records. Information regarding use of common medications in the past 20 years and potential confounding variables was obtained by telephone interview. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using an unconditional logistic regression model. Results: There were non-significant increases in risk associated with ever use of cortisone injections and oral cortisone (OR = 1.44 (Cl 0.98–2.11) for injections and 1.21 (CI 0.73–2.00) for oral cortisone, although there was no clear dose–response relationship with either type. On the other hand, the risk of NHL progressively increased with the frequency of use of non-steroidal anti-inflammatory and non-narcotic analgesic drugs (NSAID/NNAD) (p-value for trend 0.008). Women who used any of these medications daily for more than 10 years had an OR of 1.90 (CI 1.01–3.57), compared with those who used it less than once a month on average. The risk associated with long-term use was most pronounced for ibuprofen, intermediate for aspirin, and least for acetaminophen. Conclusions: Because the population-attributable risk associated with NSAID/NNAD use is potentially large, our results need to be verified in further epidemiologic studies.


Cancer Causes & Control | 2005

Personal and occupational exposure to organic solvents and risk of non-Hodgkin's lymphoma (NHL) in women (United States)

Ikuko Kato; Karen L. Koenig; Hiroko Watanabe-Meserve; Mark S. Baptiste; Patricia P. Lillquist; Glauco Frizzera; Jerome S. Burke; Miriam Moseson; Roy E. Shore

Objectives: The authors assessed whether home and occupational exposure to organic solvents is associated with risk of NHL in women.Methods: A population-based, incidence case-control study was conducted in upstate New York, involving 376 NHL cases and 463 population controls selected from the Medicare beneficiary files and State driver’s license records. Exposure information was obtained by telephone interview. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using an unconditional logistic regression model, adjusting for a number of risk factors for NHL.Results: Overall, history of exposure to organic solvents was not associated with the risk of NHL. A statistically significant increase in risk associated with occupational exposure was observed only for the subjects whose first exposure occurred before 1970 (OR=1.87, 95% CI 1.03–3.40). When occupational and home exposures to paint thinners/turpentine were combined and analyzed together, the risk of NHL associated with any exposure, compared to no exposure at either job or home, was a statistically significantly increased (OR=1.46, 95% CI: 1.05–2.03). This observation was more pronounced for B-cell lymphoma and for low-grade lymphoma with ORs of 1.52 (95 CI: 1.08–2.14) and 2.20 (95% CI; 1.42–3.41), respectively.Conclusions: The results of this case-control study do support of a major role of organic solvents in the development of NHL among women currently living in the US. However, relatively intensive exposure in past occupations and use of paint thinners/turpentine may deserve further investigation.


Environmental Health Perspectives | 2004

Pesticide Product Use and Risk of Non-Hodgkin Lymphoma in Women

Ikuko Kato; Hiroko Watanabe-Meserve; Karen L. Koenig; Mark S. Baptiste; Patricia P. Lillquist; Glauco Frizzera; Jerome S. Burke; Miriam Moseson; Roy E. Shore

A population-based, incidence case–control study was conducted among women in upstate New York to determine whether pesticide exposure is associated with an increase in risk of non-Hodgkin lymphoma (NHL) among women. The study involved 376 cases of NHL identified through the State Cancer Registry and 463 controls selected from the Medicare beneficiary files and state driver’s license records. Information about history of farm work, history of other jobs associated with pesticide exposure, use of common household pesticide products, and potential confounding variables was obtained by telephone interview. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using an unconditional logistic regression model. The risk of NHL was doubled (OR = 2.12; 95% CI, 1.21–3.71) among women who worked for at least 10 years at a farm where pesticides were reportedly used. When both farming and other types of jobs associated with pesticide exposure were combined, there was a progressive increase in risk of NHL with increasing duration of such work (p = 0.005). Overall cumulative frequency of use of household pesticide products was positively associated with risk of NHL (p = 0.004), which was most pronounced when they were applied by subjects themselves. When exposure was analyzed by type of products used, a significant association was observed for mothballs. The associations with both occupational and household pesticides were particularly elevated if exposure started in 1950–1969 and for high-grade NHL. Although the results of this case–control study suggest that exposure to pesticide products may be associated with an increased risk of NHL among women, methodologic limitations related to selection and recall bias suggest caution in inferring causation.


International Journal of Cancer | 2003

History of antibiotic use and risk of non-Hodgkin's lymphoma (NHL)

Ikuko Kato; Karen L. Koenig; Mark S. Baptiste; Patricia P. Lillquist; Glauco Frizzera; Jerome S. Burke; Hiroko Watanabe; Roy E. Shore

A population‐based, incidence case‐control study was conducted among women in upstate New York to determine whether histories of certain infections and antibiotic use are associated with risk of non‐Hodgkins lymphoma (NHL). Our study involved 376 cases of NHL identified through the New York State Cancer Registry and 463 controls selected from the Medicare beneficiary files and state drivers license records. Information about use of common medications including antibiotics, history of selected infectious diseases and potential confounding variables was obtained by telephone interview. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using an unconditional logistic regression model. There was a progressive increase in risk of NHL with increasing frequency and duration of systemic antibiotic use, as assessed over the period of 2–20 years before the interview. The ORs for the highest exposure categories, ≥36 episodes and ≥366 days of use, were 2.56 (95% CI 1.33–4.94) and 2.66 (95% CI 1.35–5.27), respectively. These associations were primarily due to antibiotic use against respiratory infections and dental conditions. Moreover, the association with frequency of antibiotic use for respiratory infections was pronounced for marginal zone B‐cell lymphoma and for respiratory tract lymphoma. Analyses by class of antibiotics did not suggest that a general cytotoxic effect of antibiotics was responsible for these increased risks. Although recall bias and selection bias remain potential concerns in our study, the results are generally consistent with the hypothesis that persistent infection/inflammation predisposes individuals to the development of NHL. However, a direct role of antibiotics in NHL induction has not been ruled out.


Neuroepidemiology | 2006

Barriers to Autopsy: Creutzfeldt-Jakob Disease in New York State

Patricia P. Lillquist; Nadia Thomas; Ermias D. Belay; Lawrence B. Schonberger; Dale L. Morse

Surveillance of Creutzfeldt-Jakob disease (CJD) monitors trends and ensures timely identification of variant CJD and other emergent prion diseases. Brain tissue is needed to definitively diagnose these diseases. A survey of neurologists and pathologists in New York State was conducted to understand neurologists’ and pathologists’ views on autopsy and CJD. Neurologists reported using autopsy rarely or never. Over half of the pathologists worked in facilities that did not perform autopsies when CJD was suspected. Barriers to autopsy included family reluctance, infection control concerns, and local facilities unable to perform brain autopsy. More accurate, complete recognition of CJD and variant forms depends on physician awareness of the manifestations of CJD and its diagnosis, access to pathologists and facilities willing and able to perform brain biopsies and autopsies, and family acceptance of such procedures.


Infection Control and Hospital Epidemiology | 2006

An investigation of potential neurosurgical transmission of Creutzfeldt-Jakob disease: challenges and lessons learned.

Rachel L. Stricof; Patricia P. Lillquist; Nadia Thomas; Ermias D. Belay; Lawrence B. Schonberger; Dale L. Morse

In 2001, New York State health officials were notified about 2 patients with Creutzfeldt-Jakob disease who had undergone neurosurgical procedures at the same hospital within 43 days of each other. One patient had Creutzfeldt-Jakob disease at the time of surgery; the other patient developed Creutzfeldt-Jakob disease 6.5 years later. This investigation highlights the difficulties in assessing possible transmission of Creutzfeldt-Jakob disease.


Journal of Public Health Management and Practice | 1998

Factors associated with repeat mammography in a New York State public health screening program.

Jennifer L. Evans; Philip C. Nasca; Mark S. Baptiste; Patricia P. Lillquist; Anne M. Stoddard; Susan J. True; Robert W. Tuthill

Screening mammography is the most effective method for early detection of breast cancer, but repeat mammography rates are not optimal in most populations. Since 1988, New York State has supported a program of breast cancer screening for underserved, uninsured, or underinsured women. The present study was designed to identify sociodemographic and clinical factors associated with failure to return for repeat mammography screening after a negative initial mammogram. Of women initially screened between 1988 and 1991 (N = 9,485), 27 percent obtained repeat mammograms by 1993. The final logistic regression model contained program site, race and ethnicity, family income, and time since last mammogram.


Social Work in Health Care | 2002

Separating the apples and oranges in the fruit cocktail: the mixed results of psychosocial interventions on cancer survival.

Patricia P. Lillquist; Julie S. Abramson

Abstract In past reviews of the literature on psychosocial interventions for cancer patients, different reviewers have reached disparate conclusions about the ability of a psychosocial intervention to have an impact on cancer survival. This article highlights some of the basis for differences of opinion, including the range of psychosocial interventions provided to patients and the challenges inherent in conducting research studies of this type. Social workers who work with cancer patients at vulnerable times need to understand what the current evidence shows can be gained from participation in a psychosocial intervention. Several key questions have been identified that can provide the basis for future rigorous studies. The role of the social worker in participating and shaping research on the relationship of psychosocial intervention and cancer survival is also discussed.


Social Work in Health Care | 2005

Can case management be used to facilitate diagnostic testing in publicly funded breast cancer screening programs

Patricia P. Lillquist

Abstract The earlier breast cancer can be diagnosed and treated, the better the odds for survival. The literature has shown many of the barriers to timely diagnosis are not individual behaviors but problems in delivery of health care. Case management has been suggested to facilitate diagnostic testing and treatment. Models of case management exist in other practice settings but have not always been rigorously described or evaluated. Determining optimal models for case management has been established federally as a research priority to ensure medically underserved women are promptly diagnosed and treated. One model has been developed and pilot-tested in this setting. This article will describe elements of case management and the characteristics of a publicly funded screening program that make use of case management to facilitate timeliness of diagnostic testing different from case management in other settings. These differences have implications for successfully implementing case management in public programs.Abstract The earlier breast cancer can be diagnosed and treated, the better the odds for survival. The literature has shown many of the barriers to timely diagnosis are not individual behaviors but problems in delivery of health care. Case management has been suggested to facilitate diagnostic testing and treatment. Models of case management exist in other practice settings but have not always been rigorously described or evaluated. Determining optimal models for case management has been established federally as a research priority to ensure medically underserved women are promptly diagnosed and treated. One model has been developed and pilot-tested in this setting. This article will describe elements of case management and the characteristics of a publicly funded screening program that make use of case management to facilitate timeliness of diagnostic testing different from case management in other settings. These differences have implications for successfully implementing case management in public programs.


Journal of health and social policy | 2001

Breast cancer policy as a paradigm for other health prevention issues: analysis of the Breast and Cervical Cancer Mortality Prevention Act of 1990.

Patricia P. Lillquist

Abstract The public policy response to breast cancer mortality is examined through an analysis of federal legislation. Departing from the federal governments traditional role in health policy, the legislation funds states to provide directly some health services related to breast and cervical cancer. The legislation establishing a national program for breast and cervical cancer screening is used as an analytic model for policy development for preventive services for other public health issues. Increased collaboration between the public health community and the social work profession is advocated.

Collaboration


Dive into the Patricia P. Lillquist's collaboration.

Top Co-Authors

Avatar

Dale L. Morse

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

Nadia Thomas

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

Ermias D. Belay

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Lawrence B. Schonberger

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ikuko Kato

Wayne State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark S. Baptiste

New York State Department of State

View shared research outputs
Researchain Logo
Decentralizing Knowledge